OUR MISSION
NASTAD’s mission is to strengthen state and territory-based and global leadership, expertise and advocacy and bring them to bear in reducing the incidence of HIV and viral hepatitis infections and on providing care and support to all who live with HIV and viral hepatitis.
NASTAD's vision is a world free of HIV/AIDS and viral hepatitis.
WHO WE ARE & WHAT WE DO
Founded in 1992, NASTAD is a non-profit national association representing the chief state health agency staff in all 50 U.S. states, the District of Columbia, Puerto Rico, the U.S. Virgin Islands and the U.S. Pacific Islands. NASTAD members have programmatic responsibility for administering state health department HIV and viral hepatitis healthcare, prevention, education and supportive service programs funded by state and federal governments.
As a national leader in health department mobilization, NASTAD encourages the use of applied scientific knowledge and community engagement as a method of reducing the incidence of HIV and viral hepatitis infections in the U.S., its territories, and around the world.
Each of NASTAD’s five programmatic teams—Health Care Access, Policy & Legislative Affairs, Viral Hepatitis, Health Equity & Prevention and Global—interpret and influence policies, conduct trainings, offer technical assistance and provide advocacy mobilization for U.S. health departments and ministries of health around the world to improve health outcomes for people living with HIV and viral hepatitis.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close